Xilio Therapeutics Inc. (XLO)
0.89
-0.02 (-1.77%)
At close: Mar 03, 2025, 11:30 AM
Company Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients.
Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.
The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases.
Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Xilio Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 22, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 73 |
| CEO | Dr. Rene Russo BCPS, Pharm.D. |
Contact Details
Address: 828 Winter Street Waltham, Massachusetts United States | |
| Website | https://www.xiliotx.com |
Stock Details
| Ticker Symbol | XLO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840233 |
| CUSIP Number | 98422T100 |
| ISIN Number | US98422T1007 |
| Employer ID | 85-1623397 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rene Russo BCPS, Pharm.D. | President, Chief Executive Officer & Director |
| Caroline Hensley | Chief Legal Officer |
| Christopher Frankenfield | Chief Operating Officer |
| Dr. Katarina Luptakova M.D. | Chief Medical Officer |
| Dr. Scott Coleman Ph.D. | Chief Development Officer |
| Dr. Uli Bialucha Ph.D. | Chief Scientific Officer |
| Kevin M. Brennan | Senior Vice President of Finance & Accounting |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 18, 2025 | SCHEDULE 13G | Filing |
| Feb 12, 2025 | 8-K | Current Report |
| Jan 21, 2025 | 8-K | Current Report |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Jan 03, 2025 | 4 | Filing |
| Dec 19, 2024 | 4 | Filing |
| Dec 19, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 19, 2024 | 8-K | Current Report |